Main content

Alert message

The Tauber Bioinformatics Research Center (TBRC), led by Prof. Leonid Brodsky, has developed a highly sophisticated machine-learning platform for mining, analysis and integration of biomedical data. This proprietary platform is user-friendly and hides the complexity of analytical tools behind an intuitive interface that can be used by non-experienced users. Innovative approaches to examine big-data coupled to a flexible infrastructure developed by the team at TBRC make complex data sets useful and available to a wide range of users: clinicians, pharma companies, researchers and even students.
Genomics and other types of “omics” and “Big Biomedical Data” have already become buzz words in healthcare and pharma. While their utility is obvious, many challenges remain – analysis, interpretation and reproducibility hinder the translation of these resources for effective development of new therapeutics that are capable of addressing unmet needs in complex diseases such as cancer and neurodegenerative disorders. TBRC’s analytic platform is a practical and elegant solution that extracts meaningful signals obscured within noisy data; identifies new associations between data groups of various types; and serves to train the next generation of users to leverage these insights

To commercialize this technology, a US-based company, Pine Biotech, has been formed to fully apply an integrated clinical platform that aggregates, normalizes and analyzes biomedical data within a clinical context. The aggregation and analysis of diverse information enables precise data-driven decisions for healthcare providers and builds a direct link to the utilization of Real World Evidence (RWE) studies critical for drug development. The company’s presentation of its platform won first place at the Pistoia Alliance President’s Startup Challenge in Boston, MA in October 2016.

Both the Research Center and its Pine Biotech affiliate have recently been included in a large Defense Advanced Research Projects Agency grant (DARPA Intercept) in collaboration with University of California San Francisco and Boston University.